Eli Lilly and Co. is facing a product liability lawsuit filed in Indiana by a North Carolina man who alleges the pharmaceutical company failed to...

Eli Lilly (NYSE: LLY) reported new exploratory data from the TOGETHER-PsO Phase 3b trial on combined Taltz and Zepbound use in adults with moderate to severe plaque psoriasis and obesity. The combination regimen affected a wider range of immunometabolic biomarkers compared with Taltz alone in the Phase 3b dataset. Investigators reported greater reductions in inflammatory immune activity with the dual therapy, alongside measures tied to metabolic health. The new TOGETHER-PsO findings on...

Eli Lilly and Co. has sued an Arizona weight loss clinic and three online sellers, alleging they are illegally selling products containing the pharmaceutical giant's investigational molecule that has not yet been approved for use in any drug, endangering consumers in a mockery of safety guidelines.

Eli Lilly and Co. has sued an Arizona weight loss clinic and three online sellers, alleging they are illegally selling products containing the pharmaceutical giant's investigational molecule that has not yet been approved for use in any drug, endangering consumers in a mockery of safety guidelines.

Eli Lilly (NYSE:LLY) stayed in focus as metabolic health demand lifted pharma, with incretin therapies and a deep pipeline shaping the day.

Eli Lilly stock costs EUR 1,049.90 on October 9, 2026 after EUR 1,040.80. Earnings follow October 29